The broad range of HIV co-morbidities: the next health challenge for PLHIV in LMICs

HHS/NIH/OAR

The broad range of HIV co-morbidities: the next health challenge for PLHIV in

LMICs

Research Priorities

Paolo G. Miotti

NIH Office of AIDS Research

23 July 2014

HOSTGeneticsLifestyle

VIRUS

AntiretroviralTherapy

Relative contributions of each of these factors to the pathogenesis of specific co-morbidities: key to develop strategies for prevention and treatment

What Contributes to the Risk of Co-morbidities in HIV?

From J. Currier (2013)

HHS/NIH/OAR

HHS/NIH/OAR

What type of research studies can provide the answers?

• Epidemiology and basic science

• Clinical science

• Implementation science

HHS/NIH/OAR

Epidemiology - Resources for research on HIV and NCDs in LMICs

• Community-based longitudinal studies

• Routine clinical databases and cohorts

• Cross-sectional demographics and health surveys (DHS)

• WHO STEP surveys

• SEARCH (Sustainable East Africa Research on Community Health)

HHS/NIH/OAR

Epidemiology - Problems with existing data sources

• Lack of population-based cohorts

• Absence of HIV-negative comparison groups

• Incomplete NCD-specific outcome ascertainment

• Incomplete measurement of key factors affecting clinical decision-making (e.g. about treatment)

HHS/NIH/OAR

International Epidemiological Database to Evaluate AIDS (IeDEA)

HHS/NIH/OAR

Basic science – The questions

• Do common pathways exist affecting different end-organ systems?

• How do we differentiate co-morbidities from cumulative treatment toxicity (ARV and other drugs)?

What’s the role of inflammation?

Inflammation↑ Monocyte activation

↑ T cell activationDyslipidemia

Hypercoagulation

Microbial translocation

HIV-associated fatMetabolic syndrome

HIV productionHIV replication

CMVExcess pathogens

Loss of regulatory cells

Co-morbiditiesAging S. Deeks, 2013

Inflammation predicts disease in treated HIV infection, as it

does in the general population

• Mortality (Kuller, PLoS Med, 2008, Sandler JID 2011, Tien JAIDS 2011)

• Cardiovascular Disease (Baker, CROI 2013)

• Lymphoma (Breen, Cancer Epi Bio Prev, 2010)

• Venous Thromboembolism (Musselwhite, AIDS, 2011)

• Type II Diabetes (Brown, Diabetes Care, 2010)

• Cognitive Dysfunction (Burdo AIDS 2012)

• Frailty (Erlandson, JID 2013)S. Deeks, 2013

A single measurement of IL-6 or D-dimers predicts morbidity or mortality over

several years

HHS/NIH/OAR

Specific NCDs in PLHIV – Some clinical questions

• Coronary arterial disease

• Neurologic diseases

• Kidney and liver

• Cancer

• Bone/muscle

• Metabolism

HHS/NIH/OAR

Coronary Arterial Disease (CAD)

• Are there HIV-specific factors driving excess CAD risk in treated disease? Monocyte activation/inflammation, hyper-coagulation, treatment toxicity

• Which interventions should be advanced to clinical endpoint studies? Statins (REPRIEVE), ASA, ACE-inhibitors, anti-inflammatory drugs

• Which biomarkers define those individuals at risk for disease and who might benefit from emerging interventions?

HHS/NIH/OAR

Neurologic Diseases

• How much harm is associated with acute HIV infection? Does early ART prevent any residual harm to CNS/PNS?

• Which neurologic conditions persist during ART? Which conditions (if any) continue to progress during ART? Does HIV replication in CNS persist during ART?

Why does inflammation persist in CNS during ART and does it matter?

HHS/NIH/OAR

Kidney and Liver

• What is role of HIV replication, HIV-associated inflammation and treatment toxicity in causing renal/hepatic dysfunction?

• Will subtle changes in renal/hepatic function - which is common - have long-term clinical implications?

• Are there strategies to prevent end-organ toxicity (e.g., ACE inhibitor and renal disease)?

• Can we develop biomarkers to detect kidney and liver damage before function is lost?

HHS/NIH/OAR

Cancer

• Which cancers are increased in HIV disease? Why are some cancers elevated while others such as

prostate/breast may be lower?

• What role does treatment toxicity, inflammation and immune deficiency have in causing cancer?

• Why are virus-associated cancers so prevalent and why are they difficult to manage? KS IRIS: cause, how to prevent?

HPV-associated anal dysplasia/cancer: how to screen/manage?

HPV-associated cervical disease in HIV-infected women: how to screen/manage in resource limit settings?

HHS/NIH/OAR

Metabolism

• Why is insulin resistance, diabetes mellitus and the metabolic syndrome common in HIV disease? Is inflammation contributing to these syndromes?

• What role do inflammatory lipids and visceral adiposity have in causing co-morbidities?

• Will some or all statins worsen some of these metabolic conditions (e.g., insulin resistance)?

HHS/NIH/OAR

Bone/Muscle

• What is role of inflammation on osteopenia/osteoporosis?

• Why does ART cause immediate depletion in BMD? Are children particularly vulnerable?

• What is role of co-infections (HCV), low testosterone, insulin resistance and metabolic syndrome in causing bone disease?

• Who should get vitamin D and bisphosphonates? Will statins be protective?

• Should adults/children be screened for bone disease?

Discovery Implementation Scale-Up

Research

W. El-Sadr, 2014

HHS/NIH/OAR

Implementation Science (I.S.)

• Addresses factors beyond clinical efficacy

• I.S. questions are about “how” (traditional scientific inquiry focuses on quantifying mean effects across samples)

• I.S. includes economic analyses, cost-effectiveness research, systems dynamics and simulation modeling, and continuous quality improvement (QI) strategies.

HHS/NIH/OAR

Research Priorities

• Estimate burden of NCDs in PLHA in diverse environments Incidence, prevalence, today and in 10, 20, … years?

• Ascertain the most important risk factors for NCDs in PLHA Prevalence, strengths of association, prediction models

• Do basic science and clinical studies in LMICs Difference between HIV-infected vs uninfected

• Do implementation science studies to compare treatment and care at individual and health systems level Integration of care, health worker education, task shifting

• Do cost-effectiveness analysis of interventions at individual and population level Point-of-care diagnosis and treatment, community health promotion

HHS/NIH/OAR

NCD echoing the lessons of HIV?

Scientific American, June 2014

HHS/NIH/OAR

Acknowledgments

• Steven Deeks, UCSF• Sten Vermund, Vanderbilt U.• Judith Currier, UCLA• Wafaa El Sadr, Columbia U.• Meg Doherty, WHO• Alan Landay, Rush U.

HHS/NIH/OAR

HHS/NIH/OAR

Incorporating recommendations for NCD prevention in general population

Consistency across programs within a region

Where might the recommendations differ? Use NCD guidance as the foundationPrioritize the issues of greatest impact for

those living HIVApplication to younger patient populationsConsider drug interactions with locally

available ART

HHS/NIH/OAR

HHS/NIH/OAR

• Type of studies needed

• Common pathogenesis

• Research priorities

NCD/Priority Areas for Guidelines Development (WHO Scoping Consultation on NCDs, July 2014)

HIGH PRIORITY NEW INFO TO BE ASSESSED IN

PLHIV

• CVD risk assessment and interventions

• Mental health screening and interventions

• Modification of ARV regimens

• Growth/puberty delay in children & adolescents

MEDIUM PRIORTIY/ MORE INFO NEEDED BEFORE

ASSESSMENT DECISION IN PLHIV

• Screening for Hep B&C

• Screening for renal dysfunction

• Bone health in children and older patients

• Behavioural changes for obesity reduction (diet and physical counselling)

• Smoking cessation

• Management of alcohol and substance abuse

LOW PRIORITYINFO ALREADY INCLUDED OR MINOR

ADJUSTMENTS CAN BE NEEDED

• Screening for cervical cancer

• Harm reduction package for Hep B&C in IDU

• HPV vaccine

• HBV vaccine

HHS/NIH/OAR

Research Priorities

• Public health surveillance and clinical epidemiology NCD incidence in PLHIV in diverse environments, NCD risk factors Mortality rates and morbidity outcomes in PLHIV

• Basic and clinical research Inflammation, coagulation, and immune mechanisms: role on NCD expression Interaction between HIV and NCD pathogenic processes Response to NCD management in different subgroups NCD biomarkersscreening tools Impact of ART regimens

• Implementation science and health systems Cost-effectiveness of POC screening tests Models of integrated NCD and HIV care Telemedicine and mobile technologies

HHS/NIH/OAR

Recommendations for observational studies of NCDs in PLHIV

• Use existing data sources, secondary data analysis Do record linkage between HIV clinical databases and registries For high prevalence NCD, add NCD to other large prospective studies

• Recruit behaviorally and demographically similar HIV pos and neg

• Address methodological challenges (selection bias, confounding, loss to F/U, competing risks)

• Facilitate collaborative research

• Build local research capacity

HHS/NIH/OAR

Implementation Science

HIV Infection

Antiretroviral Treatment

Testing, linkage to care, retention

Immune Dysfunction/Inflammation Treatment Toxicity

Anti-inflammatory drugs

Overburdened Health Care Delivery Systems

NCD Co-Morbidities

Preventive medicine

Co-occurring chronic diseases

Operational research

Research and clinical priorities in the era of “complete “ viral suppression: Test and treat, reduce inflammation, insure

healthy aging, and provide chronic care (until there is a cure)

S. Deeks, Lancet (2013)

Early ART is associated with less inflammation during ART

Will this result in benefit?

ART-naïve with CD4+ count > 500 cells/mm3

Early ART Group

Initiate ART immediately

N=2,300

Deferred ART Group

Defer ART until the CD4+ count declines to < 350 cells/mm3

N=2,300

START

HHS/NIH/OAR

HIV is now a chronic disease requiring treatment for many decades

• Persistent inflammation/immune dysfunction• Subtle but cumulative ART toxicity• Additional co-morbidities (non-AIDS events)• Clinical aging

modified from S. Deeks, 2013

HHS/NIH/OAR

Chronic Infectious Diseases

• How does TB, malaria, hepatitis and other highly prevalent infectious disease impact HIV and overall health?

• How should TB and LTBI be diagnosed and treated? True point of care diagnostics with improved sensitivity Shorter drug sensitive regimens & more effective MDR regimens that are

compatible with ART

• How does HCV drive comorbidity with HIV? Synergistically increased inflammation or acting via independent pathways? Will there be residual issues in era of direct acting antiviral drugs?

HIV and NCD co-morbidities

HHS/NIH/OAR

Stepped wedge study design

HHS/NIH/OAR

Implementation science (I.S.)

The scientific study of methods and strategies to promote the systematic uptake of clinical research findings and other evidence-based practices into routine practices and, hence, to improve quality (effectiveness, safety appropriateness, equity, cost-efficiency) of health care

HHS/NIH/OAR

Low-resource countries – Medium/long term scenario

• People taking ART will take them for decades

• The larger number of people taking ART may overburden the health systems of many LMICs

• Effects of new WHO Guidelines (2013)

HHS/NIH/OAR

HIV co-morbidities - What organ systems are affected?

• Cardiovascular disease

• Cancer

• Neurologic and cognitive

• Metabolic and bone

• Kidney

• Liver, gastrointestinal, and nutritional

• Lung

• Co-infections

HHS/NIH/OAR

HIV and NCD co-morbidities

The broad scientific question:

Are there differences between these HIV co-morbidities in high-income vs. low and middle income countries (LMICs)?

HHS/NIH/OAR

HIV and NCD co-morbidities – Key points

• Type of studies needed

• Common pathogenesis

• Research priorities

HHS/NIH/OAR

WHO Package of Essential NCD (PEN) tools in low-resource settings

WHO- Package of Essential NCD (PEN) Interventions (2010) (partial list)

HHS/NIH/OAR

HIV and NCD co-morbidities

To impact population health:

How should these HIV co-morbidities be diagnosed and managed in LMICs?

HHS/NIH/OAR

The epidemiology and the data

• Specific HIV co-morbidities and regional HIV epidemics

• Identify biomarkers and other indicators to screen for co-morbidities and predict outcomes

• Use above data to devise training algorithms for health workers to effectively address co-morbidities in LMICs

HHS/NIH/OAR

The epidemiology and the data

• Scanty data make it difficult to answer main question: “do HIV populations in LMIC have excess risk of NCD?”

• To devise sustainable interventions, use evidence from multiple sources, e.g. clinical care cohorts, interval cohorts (prospective studies), demographic & health surveys, WHO STEP surveillance

HHS/NIH/OAR

How important are studies of NCD in PLWHA in LMIC?

• The main unmet goal is getting ART to all in need and be able to do so for many years

• But studies of NCD co-morbidities in PLHA are important because too little is known about their prevalence, characteristics and management in LMIC

HHS/NIH/OAR

Things to do

– Identify data gaps– Identify questions of interest

• to investigators• to implementing agencies (e.g. PEPFAR)

– Provide evidence base for Guidelines (e.g. WHO Guidelines)

– Test research findings in cost-effectiveness models

– Synergies & Partnerships

HHS/NIH/OAR

HIV and NCD co-morbidity in LMIC– A Systematic Review

• Systematic review of studies from Medline and Embase (2000-2012)

• Magnitude and determinants of NCDs in PLHA

• 37 studies (25 from Africa), 20 countries, 31344 PLHA• CVD: in >1/3 clinic attenders (myocardial and conduction

disorders more common than vascular)• Cancer: relatively low prevalence of AIDS def. and non-AIDS

def. cancers, but high pre-cancerous lesions (cervical SIL)• Diabetes: < 5% (young patients?). DM-TB relationship?• Metabolic abnormalities (incl. dyslipidemia):13-28%

HHS/NIH/OAR

HIV as a chronic disease (cont’d)

Studies of co-morbidities in PLWHA require investigating:

• Different (additional) risk factors

• Different level of disease expression

• More and different drug toxicities (ARV and other drugs)

What are the most pressing questions regarding the

pathogenesis and management of organ

system dysfunction/disease?

What are the most pressing questions regarding the

pathogenesis and management of organ

system dysfunction/disease?

Deeks, Immunity 2013

Potential Clinical Consequences of Microbial Translocation

Therapeutic Options in Development

• Chemokine receptor inhibitors: maraviroc, TB-652

• Anti-infective therapy: CMV, EBV, HSV, HCV/HBV

• Microbial translocation: sevelamer, colostrum, rifaximin, pre-biotics, probiotics, isotrentinoin

• Enhance T cell renewal: growth hormone, IL-7

• Anti-fibrotic drugs: perfenidone, ACE inhibitors, ARBs

• Anti-aging: caloric restriction, sirtuin activators, vitamin D, omega-3 fatty acids, sirolimus, diet, exercise

• Anti-inflammatory drugs– Chloroquine,

hydroxychloroquine– Minocycline– NSAIDs (COX-2 inhibitors),

aspirin– Statins– Methotrexate (low-dose; CIRT) – Talidomide, lenalidomide,

pentoxyfylin– Biologics (e.g., TNF inibitors,

IL-6 inhibitors, anti-INF-alpha)• Anti-coagulants: low dose

warfarin, dabigatran, aspirin, clopidogrel

Deeks IAS 2013

Immunesuppression

Lancet, series on NCDs

59

The Lancet

HHS/NIH/OAR60

Some limitation of studies of NCDs in HIV+ patients

• Independant markers of NCD causality

Need for predictive markers

• Use of surrogate outcomes

• Age adjustement needed to assess accentuated vs accelerated risk

• Confounding factors

HHS/NIH/OAR

Co-morbidity – Cardiovascular / pulmonary

• Hypertension

• Cardiomyopathy

• Pericarditis/pericardial effusion

• Pulmonary arterial hypertension

• Ischemic heart disease, coronary disease, large vessel disease: role in LMIC?

HHS/NIH/OAR

Co-morbidity – Malignancies

• AIDS-defining cancers– Kaposi sarcoma– Non-Hodgkin lymphoma– Cervical (invasive, mostly squamous cell)

• Non AIDS-defining cancers– Hodgkin lymphoma– Anal and colorectal– Liver (HCC) – Lung

HHS/NIH/OAR

Co-morbidity – Mental, neurological and substance use

1. Depression

2. Alcohol abuse

3. HIV-associated neurocognitive disorders (HAND)

1+2+3: WHO Mental Health GAP Action Programme

HHS/NIH/OAR

Co-morbidity – Metabolic and bone

• Diabetes

• Dysglycemias

• Dyslipidemias

• Body composition changes– lipodystrophy– obesity

• Bone mineral density abnormalities

HHS/NIH/OAR

Co-morbidity – renal and genito-urinary

• HIV-associated nephropathy (HIVAN): genetic predisposition (MYH9 and APOL1 genes on chromosome 22)

• Hypertension and kidney disease

• Genetic overlap between risk of hypertension, focal segmental glomerulosclerosis (FSGS) and HIVAN

• Genito-urinary: kidney stones related to ART, prostatitis

HHS/NIH/OAR

Co-morbidity – GI, hepatic and nutritional

• Liver disease: major mortality in high resource countries

HBV, HCV, HDV associated hepatotoxicity

Medication-related hepatotoxicity

Non-alcoholic fatty liver disease (NAFLD)

Hepatocellular carcinoma (HCC)

• Malnutrition and ART

HHS/NIH/OAR

Co-morbidity – Obstructive lung disease-

• Difference in population risk factors

• Environmental exposures

• Diagnostic limitations

• Clinical and implementation issues

HHS/NIH/OAR

Low income & middle income countries(LMIC)

World Bank definition using annual Gross National Income (GNI) per capita (2013):

• Low $ 1,035 or less

• Low-middle $ 1,036-4,085

• Upper-middle $ 4,086-12,615

• High $ 12,616 or more

HHS/NIH/OAR

Essential interventions for NCDs in low resource settings

HOSTGeneticsLifestyle

Virus/Immune System

AntiretroviralTherapy (ART)

Relative contributions of each of these factors to the pathogenesis of specific co-morbidities: key to develop strategies for prevention and treatment

What Contributes to the Risk of Co-morbidities in HIV?

More than 50% of HIV-infected adults age 55-60 had >2 co-morbidities, a number higher than HIV-uninfected adults who are a decade older

Peter Reiss et al, U. of Amsterdam

HHS/NIH/OAR

Recommendations for observational studies of NCDs in PLHIV

• Use existing data sources, secondary data analysis Do record linkage between HIV clinical databases and registries (hospital,

pharmacy, lab and mortality registries) For high prevalence NCD, add NCD to other large prospective studies

• Recruit behaviorally and demographically similar HIV pos and neg individuals

• Assess core risk factors for NCD and variables influencing clinical decision making

• Disentangle effects of HIV on NCD from HIV-NCD associations due to confounding

HHS/NIH/OAR

Recommendations for observational studies of NCDs in PLHIV (cont’d)

• Address methodological challenges (selection bias, confounding, informative missingness and loss to F/U, competing risks)

• Facilitate collaborative research – Do meta-analyses of individual participant data (IPD) to overcome limited power

of single studies– Compare predictions from different mathematical models

• Build local research capacity

HHS/NIH/OAR

Coronary Arterial Disease (CAD)

• Are there HIV-specific factors driving excess CAD risk in treated disease? Monocyte activation/inflammation, hyper-coagulation, treatment toxicity

• Why is sudden cardiac death so common in treated HIV disease?

• Which interventions should be advanced to clinical endpoint studies? Statins (REPRIEVE), ASA, ACE-inhibitors, anti-inflammatory drugs

(MTX)

• Which biomarkers might define those individuals at risk for disease and who might benefit from emerging interventions?